Paxlovid may have slight advantage against death, according to one study.
Both Paxlovid, molnupiravir lower COVID Omicron deaths, hospitalizations, studies conclude
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Study: Before vaccines, 44% of COVID-19 patients in ICU died
- Hospital COVID patients 35% more likely to die than flu patients last winter, study suggests
- FDA warns of false results from Cue Health COVID tests
- COVID patient testing, isolation of sick staff cut in-hospital viral spread, modeling study suggests